蓝帆医疗：9月22日召开董事会会议

Group 1 - The core point of the article is that Bluestar Medical announced a board meeting to discuss the adjustment of the conversion price of "Bluestar Convertible Bonds" [1] - For the first half of 2025, Bluestar Medical's revenue composition is as follows: 70.08% from rubber and plastic products, 24.88% from specialized equipment manufacturing, 3.72% from other manufacturing, and 1.32% from other businesses [1] - As of the report, Bluestar Medical has a market capitalization of 5.7 billion yuan [1] Group 2 - The article highlights a national large-scale procurement that has drawn significant attention from the industry due to concerns over low bidding prices [1]